{"schema_version":"secwatch.filing_event.v1","accession":"0001651308-23-000025","form_type":"8-K","ticker":"ONC","cik":"0001651308","company_name":"BeOne Medicines Ltd.","filed_at":"2023-01-31T23:59:59+00:00","discovered_at":"2026-05-14T18:03:46.008323+00:00","generated_at":"2026-06-20T05:28:19.052516+00:00","sec_items":["1.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Amgen relinquishes board appointment right at BeiGene; Hooper remains","bullets":["Amgen gave up its right to designate a director to BeiGene's board under an amendment to the 2019 Share Purchase Agreement.","Anthony C. Hooper, Amgen's former designee, will continue serving as director on BeiGene's board until his term ends in 2025.","The amendment was effective January 30, 2023; Amgen cited BeiGene's global growth as the reason for relinquishing the right.","Amgen invested approximately $2.78 billion in BeiGene in 2019, receiving shares and board appointment rights."],"urls":{"canonical":"https://secwatch.observer/filing/0001651308-23-000025","json":"https://secwatch.observer/filing/0001651308-23-000025.json","markdown":"https://secwatch.observer/filing/0001651308-23-000025.md","text":"https://secwatch.observer/filing/0001651308-23-000025.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1651308/000165130823000025/0001651308-23-000025-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1651308/000165130823000025/bgne-20230130.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-20T05:28:19.052516+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"237128f2c4828c8c3ac1789f118a52a0ead0b846","claim":"BeOne Medicines Ltd. amended Amendment No. 3 to the Share Purchase Agreement with Amgen Inc. (effective 2023-01-30).","evidence_excerpt":"On January 30, 2023, on account of the Company’s global growth, Amgen elected to relinquish its right to appoint a designated director to the Company’s board of directors, pursuant to an Amendment No. 3 to the Share Purchase Agreement (the “Amendment”).","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1651308/000165130823000025/0001651308-23-000025-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"amendment"},{"label":"Agreement","value":"equity purchase"},{"label":"Counterparty","value":"Amgen Inc."},{"label":"Effective","value":"2023-01-30"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}